News

Castellum, Inc. Announces Pricing of $3,000,000 Public Offering and NYSE Listing

POTOMAC, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE: CTM) (“Castellum”, or the “Company”), a cybersecurity, electronic warfare,…

2 years ago

BioSyent Initiates First Dividend

MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…

2 years ago

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

•  No safety concerns noted in ongoing clinical trial•  Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE…

2 years ago

Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022

TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services…

2 years ago

Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER

Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDERClaude Poliart, founder and manager…

2 years ago

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

Novel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY),…

2 years ago

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on…

2 years ago

BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”…

2 years ago

Sientra Announces Preliminary Unaudited Third Quarter Financial Results and Signing of Senior Secured Loan Facilities With Deerfield Management

Anticipates total third quarter net sales of $21.5-$22.5 million, up 10-15% compared to the prior year period Restructured balance sheet…

2 years ago

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech…

2 years ago